RESEARCH TRIANGLE PARK – Three publicly traded Triangle-based biotech and pharmaceutical firms are all reporting losses for their most recent quarter.
The details:
Chimerix loses $73.7M
Chimerix Inc. (CMRX) on Tuesday reported a loss of $73.7 million in its third quarter.
On a per-share basis, the Durham, North Carolina-based company said it had a loss of $1.26. Losses, adjusted for costs related to mergers and acquisitions, came to 15 cents per share.
The biopharmaceutical company posted revenue of $2 million in the period.
The company’s shares closed at $1.46. A year ago, they were trading at $3.75.
Aerie reports $49M loss
Aerie Pharmaceuticals Inc. (AERI) on Wednesday reported a loss of $49.4 million in its third quarter.
The North Carolina, North Carolina-based company said it had a loss of $1.09 per share. Losses, adjusted for non-recurring costs, were 86 cents per share.
The results fell short of Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for a loss of 84 cents per share.
The drugmaker posted revenue of $18.5 million in the period, which beat Street forecasts. Five analysts surveyed by Zacks expected $17.6 million.
Aerie shares have declined 34% since the beginning of the year. In the final minutes of trading on Wednesday, shares hit $23.82, a drop of 56% in the last 12 months.
BioCryst loses $38M
BioCryst Pharmaceuticals Inc. (BCRX) on Wednesday reported a loss of $37.6 million in its third quarter.
On a per-share basis, the Durham, North Carolina-based company said it had a loss of 34 cents.
The results fell short of Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for a loss of 31 cents per share.
The drugmaker posted revenue of $1.8 million in the period, also missing Street forecasts. Four analysts surveyed by Zacks expected $4.5 million.
The company’s shares closed at $2.03. A year ago, they were trading at $7.93.
